Crown Bioscience and MBL Enter Joint Venture to Provide Advanced Preclinical Services for Japanese Customers
12.5.2022 09:00:00 EEST | Business Wire | Press release
Crown Bioscience and Medical & Biological Laboratories (MBL), JSR Life Sciences companies, today announced the formation of a joint venture, to further expand the provision of Crown Bioscience’s preclinical services to Japanese customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220511005724/en/
Crown Bioscience and MBL Enter Joint Venture to Provide Advanced Preclinical Services for Japanese Customers (Photo: Business Wire)
The new entity named “Crown Bioscience & MBL”, is a long-term strategic partnership that is expected to accelerate growth for both companies. The initial focus is to provide preclinical and translational services to expand Crown Bioscience’s offerings in Japan. The agreement will enhance Crown Bioscience’s current distributor model and establish a local presence to ensure premium service delivery in Japan.
Based in Tokyo, Crown Bioscience & MBL will establish a local team led by an experienced General Manager, Hiroki Itou, Executive Officer of MBL and General Manager, Diagnostic & Research Reagents Department at JSR.
The new company will leverage each organisations’ respective areas of excellence and expertise, combining Crown Bioscience’s world-class preclinical and translational service capabilities with MBL’s deep knowledge and experience of the Japanese pharmaceutical market. The company, established in April 2022, is expected to initiate services from September 2022.
Commenting on the establishment of the new company, Armin Spura PhD, CEO of Crown Bioscience, noted that the agreement will extend and deepen the current partnership with MBL. He said: “Japan will play a significant part in Crown Bioscience and MBL’s long-term strategic vision. Our new company has been created to better serve the evolving needs of the Japanese biopharmaceutical community, and to serve our Japanese customers more effectively. I am excited to further develop our synergies with MBL – a trusted partner in the Japanese life sciences sector.”
Hiroki Itou, President of Crown Bioscience & MBL commented: “Our two companies share a deep respect and identical values in the way we conduct business. I am confident that together we will be able to provide a unique and innovative portfolio of services that will accelerate drug discovery and development in Japan.”
###
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) providing preclinical and translational platforms to advance oncology, immuno-oncology, and immune-mediated inflammatory diseases (IMID). The company is the only preclinical CRO to provide tumor organoid services utilizing HUB technology and has the world’s largest commercially available PDX collection. Crown Bioscience helps deliver superior drug candidates to ensure that patients get the right treatment at the right time. Founded in 2006, Crown Bioscience has ten facilities in the US, Europe and Asia. Find out more: www.crownbio.com.
About Medical & Biological Laboratories Co., Ltd.
Medical & Biological Laboratories (MBL) was established in 1969 as the first antibody manufacturer in Japan, and researches, develops, manufactures, and sells reagents of in vitro diagnostics (IVD) and reagents for basic research. It has now expanded its business not only to the immunological field but also to the field of genetic diagnosis. In the IVD business, we develop and sell IVD reagents for autoimmune diseases, cancer, infectious diseases, etc. Particularly in the field of autoantibody diagnosis, we are expanding our product lineup as a top manufacturer in Japan and contributing to medical care in this field where there are many intractable diseases. In the field of oncology, we are contributing to personalized medicine by developing companion diagnostics that predict the effects of drugs.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220511005724/en/
Contact information
Media Enquiries:
Crown Bioscience
Louise Stenson
pr@crownbio.com
Medical & Biological Laboratories
Youichi Kozuka
kouhou@mbl.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HJS Foundation Releases JEP Protocol & HJS Framework: The "Black Box" for AI, Enabling Verifiable Human Oversight24.3.2026 05:36:00 EET | Press release
HJS Foundation (Human Judgment Systems Foundation) today released two complementary solutions: the Judgment Event Protocol (JEP) and the Human Judgment Structure (HJS) framework. As a minimalist open standard, JEP generates tamper-proof records of AI decision accountability, just like an aircraft black box; HJS embeds human judgment logic into AI operation processes — together, they transform "human oversight" from a regulatory requirement into a verifiable technical fact, providing an optional technical solution for AI accountability. How to prove that AI decisions (such as loan approvals, medical diagnoses, border screenings, etc.) have undergone human review? JEP generates immutable audit trails of human intervention through four cryptographic primitives — Judge, Verify, Delegate, Terminate; HJS builds a controllable and accountable system to prevent risks such as AI drift and ensure that human judgment guides AI operations. Current systems rely on alterable post-hoc documentation,
Access Advance Welcomes New VDP Pool Licensors and Releases Independent Economic Analysis Confirming FRAND Compliance24.3.2026 02:00:00 EET | Press release
Access Advance LLC today announced that Sharp Corporation, CB Cline, SK Planet, and Telechips, Inc have joined the Access Advance Video Distribution Patent Pool (VDP Pool) as Licensors, further expanding the pool's portfolio of patents for modern video codec technologies (HEVC, VVC, VP9, and AV1). The announcement coincides with the release of an independent economic analysis by Criterion Economics confirming that the VDP Pool's royalty structure is fair, reasonable, and nondiscriminatory (FRAND). Sharp, a global leader in consumer electronics and display technologies, brings decades of research and development in video processing and compression to the VDP Pool. The additions of CB Cline, SK Planet, and Telechips, Inc further expand the pool’s patent coverage. These additions reinforce the VDP Pool’s position as the leading licensing program for modern video codec technologies powering the streaming experiences of consumers worldwide. "Sharp, CB Cline, SK Planet, and Telechips each br
Power Integrations Extends Flyback Topology to Enable 440 W, Offering Simpler Alternatives to Resonant Power Designs23.3.2026 23:45:00 EET | Press release
APEC 2026 – Power Integrations (NASDAQ: POWI), the leader in high-voltage integrated circuits for energy-efficient power conversion, today introduced a breakthrough in flyback topology extending the power range of flyback converters to 440 W—well beyond the limits that traditionally required more complex resonant and LLC topologies. The new TOPSwitchGaN™ flyback IC family unites the company’s groundbreaking PowiGaN™ technology with its iconic TOPSwitch™ IC architecture, reducing complexity, eliminating heat sinks in many cases, shortening design time, improving manufacturability, and lowering total system cost. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323686299/en/ The new TOPSwitchGaN™ flyback IC family extends the power range of flyback converters to 440 W—well beyond the limits that traditionally required more complex resonant and LLC topologies. “This is more than a product evolution—it’s a fundamental shift in
I-Pulse Announces Strategic Partnership to Advance Geothermal Pulsed Power Applications in the Millungera Basin, Australia23.3.2026 23:40:00 EET | Press release
I-Pulse Co-Founder, Chairman, and CEO Robert Friedland, I-Pulse Co-Founder and Head of Technology Laurent Frescaline, and Sunrise Energy Metals Managing Director Sam Riggall, are delighted to announce a partnership to deploy and validate I-Pulse’s G-Pulse pulsed power drilling technology in the Millungera Basin, a large-scale geothermal clean energy resource located in northwest Queensland, Australia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323421297/en/ Left: Millungera Basin location in Queensland, Australia. Right: Millungera Basin (in brown) to the east of the Mt Isa Inlier (in red) and EPG permit areas. Under an earn-in agreement, I-Pulse will assume operational control and funding of the Millungera Basin Geothermal Project through a capital-light, technology-driven joint venture structure. Sunrise remains a free-carried minority holder of the site, ensuring alignment, continuity and local resourcing, while I-
The Estée Lauder Companies’ Statement on Potential Transaction with Puig23.3.2026 22:15:00 EET | Press release
The Estée Lauder Companies Inc. (NYSE: EL) confirms that it is in discussions regarding a potential business combination with Puig, in which the two companies would potentially merge their businesses. No final decision has been made, and no agreement has been reached. Unless and until an agreement is signed between the companies, there can be no assurances regarding the deal or its terms. Forward-Looking Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding a potential transaction and the anticipated timing, terms, and completion of any such transaction. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the possibility that no agreement will be reached, tha
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom